The study is being conducted to compare the pharmacokinetics and safety of HRS-7535 in subjects with mild to moderate hepatic impairment and normal hepatic function.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Oral HRS-7535 tables.
Henan Provincial Infectious Disease Hospital
Zhengzhou, Henan, China
RECRUITINGThe maximum plasma concentration of HRS-7535 (Cmax)
Time frame: Post-dose at day 1 to day 4.
Area under the concentration curve from time 0 to the last quantifiable concentration (AUC0-t)
Time frame: Post-dose at day 1 to day 4.
Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf)
Time frame: Post-dose at day 1 to day 4.
Time to maximum plasma concentration (Tmax)
Time frame: Post-dose at day 1 to day 4.
Terminal half-life (t1/2)
Time frame: Post-dose at day 1 to day 4.
Apparent clearance (CL/F)
Time frame: Post-dose at day 1 to day 4.
Apparent volume of distribution (Vz/F)
Time frame: Post-dose at day 1 to day 4.
Adverse events (AEs)
Time frame: Screening period up to Day 7.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.